Trials / Active Not Recruiting
Active Not RecruitingNCT05701800
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
A Phase 1/2, Randomized, Observer-Blind, Active-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity and Immunogenicity of mRNA-1468, a Candidate Vaccine to Prevent Herpes Zoster (HZ) in Healthy Adults ≥50 Years of Age
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 659 (actual)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this first-in-human study is to evaluate the safety and immunogenicity of mRNA-1468.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | mRNA-1468 | Sterile liquid dispersion for injection |
| BIOLOGICAL | Placebo | Sterile liquid for injection |
| BIOLOGICAL | Shingrix | Sterile suspension for injection |
Timeline
- Start date
- 2023-01-23
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2023-01-27
- Last updated
- 2025-08-13
Locations
20 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05701800. Inclusion in this directory is not an endorsement.